Shares of Aerie Pharmaceuticals, Inc. (AERI) are higher by nearly 47% to $19.50 in early trade on Tuesday after the company reported that the FDA has agreed in written and verbal communications that Aerie may change the primary endpoint range of its second Phase 3 registration trial of RhopressaTM, named Rocket 2.
“We are extremely pleased with the outcome of our communications with the FDA. If Rocket 2 results resemble those of Rocket 1, we believe we may have a much greater opportunity for success in meeting the clinical endpoint of non-inferiority to timolol, ” commented Vicente Anido, Jr., Ph.D., Chairman and CEO of Aerie Pharmaceuticals, a company focused on the discovery of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
Acura Pharmaceuticals, Inc. (ACUR) shares surged 27.72% to $1.06 in early trading after the company announced a License and Development Agreement with Bayer Healthcare (BAYRY), for licensing of Acura’s IMPEDE technology. Bayer has the right to negotiate for a worldwide license to the IMPEDE technology for additional products.
Great Basin Scientific Inc (GBSN) shares are rallying, up nearly 18 percent to $3.66 on Tuesday morning on news the European Patent Office has issued a notice to allow for application (#09711952.3) for the Great Basin’s on-chip amplification technology, currently patented in the U.S.
Shares of Coty Inc. (COTY) are up $3.57, or over 13.70%, at $29.62, following a Reuters report that said the company has won auctions to acquire three businesses from Procter & Gamble Co (PG) for as much as $12 billion. According to the publication, Coty outbid other potential buyers vying for P&G’s hair-care, fragrant and cosmetics businesses.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!